C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
2.670
+0.080 (3.09%)
At close: Dec 5, 2025, 4:00 PM EST
2.710
+0.040 (1.50%)
Pre-market: Dec 8, 2025, 4:39 AM EST
C4 Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover C4 Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $8.50, which forecasts a 218.35% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $10.
Price Target: $8.50 (+218.35%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 23, 2025.
Analyst Ratings
The average analyst rating for C4 Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 3 | 3 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Dec 2, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $5 → $10 | Buy | Maintains | $5 → $10 | +274.53% | Sep 23, 2025 |
| Barclays | Barclays | Buy Maintains $8 → $10 | Buy | Maintains | $8 → $10 | +274.53% | Sep 23, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $6 | Buy | Reiterates | $6 | +124.72% | Sep 22, 2025 |
| Barclays | Barclays | Buy Initiates $8 | Buy | Initiates | $8 | +199.63% | Sep 17, 2025 |
Financial Forecast
Revenue This Year
32.83M
from 35.58M
Decreased by -7.73%
Revenue Next Year
22.03M
from 32.83M
Decreased by -32.90%
EPS This Year
-1.56
from -1.52
EPS Next Year
-1.44
from -1.56
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 37.8M | 42.0M | ||||
| Avg | 32.8M | 22.0M | ||||
| Low | 27.4M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 6.2% | 27.9% | ||||
| Avg | -7.7% | -32.9% | ||||
| Low | -22.9% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.26 | -0.89 | ||||
| Avg | -1.56 | -1.44 | ||||
| Low | -1.95 | -2.55 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.